Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 6Cardiotoxicity 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 3Neuroblastoma 2Leukemia 2Vomiting 1Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Nausea 1Lymphoma, Large-Cell, Anaplastic 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Extravasations of Anthracycline Anti-cancer Agents 1Extravasation 1Drug-Related Side Effects and Adverse Reactions 1Dermatofibrosarcoma 1Degradation of Top2b and Top2a in Human by Dexrazoxane 1

Interventions

Razoxane 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Extravasation × Dexrazoxane × Clear all
NCT00548704 2015-10-21

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Valerio Therapeutics

Phase 2/3 Completed
57 enrolled

Extravasation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡